Use to detect activating BRAF mutations at codon 600, which can indicate responsiveness to BRAF inhibitors in melanomas or resistance to anti-EGFR therapy in colorectal cancer. May be useful in assessing prognosis of certain thyroid cancers. This test is also used within the Lynch syndrome reflex testing pathway (for colorectal cancer specimens only).
Assay: Mon, Wed, Fri
- Patient Preparation
- Tumor tissue.
- Specimen Preparation
- Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 5 unstained 5-micron slides. (Min: 3 slides). Tissue block will be returned after testing.
Transport block and/or slide(s) in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.
- Storage/Transport Temperature
- Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
- Unacceptable Conditions
- Less than 25 percent tumor. Specimens fixed/processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives. Decalcified specimens.
- Include surgical pathology report.
- Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
|Component Test Code*||Component Chart Name||LOINC|
|2002524||BRAF Codon 600 Mutation Detection||58483-9|
- BRAF Gene Mutation Assay
- BRAF Mutation Analysis
- EGFR targeted therapy
- sporadic Lynch Syndrome